[MAGE: Cover | Apalutamide Intermediate production facility | alt="Apalutamide intermediate production equipment at Haohong Pharmaceutical plant"]

Haohong: High-Grade Pharmaceutical Intermediates for Targeted Cancer Drug Synthesis

Introduction

Pharmaceutical intermediates are the foundational building blocks for active pharmaceutical ingredients (APIs). In the development of targeted cancer therapies—such as Apalutamide, Alectinib, and Abemaciclib—the purity, consistency, and supply reliability of these intermediates directly impact drug safety, efficacy, and time-to-market. Haohong (Qihe) Pharmaceutical Technology Co., Ltd. specializes in the R&D and custom production of high-grade pharmaceutical intermediates designed specifically for anti-cancer, anti-hepatitis C, and anti-diabetic therapies. With a dedicated R&D team of 30 engineers and an annual production capacity of 1,000 tons, the company serves a global customer base across the United States, Europe, Japan, India, Bangladesh, and other regions.

What Are Pharmaceutical Intermediates and Why Do They Matter?

Pharmaceutical intermediates are pre-semi-finished compounds obtained during the multi-step synthesis of an API. They bridge fine chemicals and finished drugs. For advanced oncology projects, intermediates must meet stringent specifications for chirality, halogenation, and functional-group purity. Impurities or variability at the intermediate stage can cascade into failed batches or compromised patient safety. Therefore, sourcing from a supplier with proven quality systems, like ISO 9001:2015 certification (obtained by Haohong in 2021), is essential.

[MAGE: Supporting | API synthesis conceptual diagram | alt="Pharmaceutical intermediate synthesis process: from raw chemicals to API"]

Industry Context: Rising Demand for Oncology Intermediates

The global shift toward targeted therapies and personalized medicine has increased the need for structurally complex, high-purity intermediates. Companies must balance R&D agility with commercial-scale production. Haohong, established in 2021 in Qihe County High-tech Zone, Shandong Province, was built with this challenge in mind. It operates a 3,000-square-meter facility with 30 reactors (3,000–5,000 L each) in Liaocheng, enabling both gram-scale custom synthesis and bulk supply. Export business accounts for 40% of total sales, with major markets including the U.S., Europe, Japan, India, and Bangladesh.

Haohong’s Core Intermediate Product Lines

Apalutamide Intermediates

Haohong’s Apalutamide intermediate product line includes multiple chemical intermediates such as 2-Fluoro-4-nitrobenzoic acid (CAS 403-24-7, purity ≥98.0%), N-Methyl-2-fluoro-4-nitrobenzamide (CAS 915087-24-0, purity ≥98.0% by HPLC), N-Methyl-2-fluoro-4-aminobenzamide, N-Methyl-2-fluoro-4-bromobenzamide, Methyl 4-bromo-2-fluorobenzoate, 2-Hydroxy-5-nitro-3-(trifluoromethyl)pyridine, and 5-Amino-3-(trifluoromethyl)pyridinecarbonitrile. These compounds serve as key fluorinated and nitro-substituted aromatic building blocks for the synthesis of Apalutamide, a next-generation androgen receptor inhibitor.

Alectinib Intermediates

For Alectinib—a potent ALK inhibitor used in non-small cell lung cancer—Haohong supplies three critical intermediates: 2-(4-Ethylphenyl)-2-methylpropanoic acid (CAS 1247119-83-0, purity ≥98%), 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid (CAS 1256584-73-2, purity ≥98%), and tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate (CAS 1256584-75-4, purity ≥98% by HPLC). The latter is an indole heterocyclic compound that requires storage at 2–8°C, sealed and protected from light.

[MAGE: Supporting | Alectinib Intermediate structure | alt="Alectinib intermediate chemical structure tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate"]

Abemaciclib Intermediates

The Abemaciclib intermediate product line comprises five compounds: 4-Bromo-2,6-difluoroaniline (CAS 1868-81-7, purity ≥98.0% by HPLC/GC), 5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-amine (CAS 398565-53-2, purity ≥98.0% by HPLC), 2-Bromo-5-formylpyridine (CAS 100422-52-6, purity ≥98.0% by GC/HPLC), 4-Fluoro-2-methyl-1-isopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole (CAS 1356339-86-7, purity ≥98.0% by HPLC), and 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole (CAS 1356339-85-6, purity ≥98.0% by HPLC). These halogenated and boronic ester intermediates are essential for constructing the CDK4/6 inhibitor Abemaciclib.

How to Evaluate and Select Pharmaceutical Intermediates

1. Verify purity specifications – Haohong provides ≥98.0% purity for most intermediates, with batch-specific COA including HPLC/GC data.
2. Check storage conditions – Many intermediates require strict temperature control (2–8°C), inert atmosphere, and light protection to maintain stability.
3. Assess scaling capability – Haohong offers custom synthesis from gram scale up to hundreds of kilograms, supported by a 1,000-ton annual capacity and 30 sets of 3,000–5,000 L reactors.
4. Confirm quality certifications – ISO 9001:2015 certification (2021) and recognition as a Technology-based SME (2024) and Innovative SME of Shandong Province (2025) demonstrate commitment to quality.
5. Review export experience – Products are exported to the U.S., Europe, Japan, India, Bangladesh, and others, indicating compliance with international standards.

Use Cases: Anti-Cancer and Anti-Viral Drug Projects

Haohong’s intermediates are deployed in anti-cancer and anti-viral drug projects. The application scenario is particularly active in China and global markets. The company’s intermediates are used as key raw materials for synthesizing APIs, simplifying R&D and production processes for innovative and generic drug manufacturers.

Product Comparison: Selected Haohong Intermediates

Intermediate Name	CAS Number	Purity	Primary Application
2-Fluoro-4-nitrobenzoic acid	403-24-7	≥98.0%	Apalutamide
N-Methyl-2-fluoro-4-nitrobenzamide	915087-24-0	≥98.0% (HPLC)	Apalutamide
2-(4-Ethylphenyl)-2-methylpropanoic acid	1247119-83-0	≥98%	Alectinib
tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate	1256584-75-4	≥98% (HPLC)	Alectinib
4-Bromo-2,6-difluoroaniline	1868-81-7	≥98.0% (HPLC/GC)	Abemaciclib
6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole	1356339-85-6	≥98.0% (HPLC)	Abemaciclib

[MAGE: Proof | Abemaciclib intermediate specification | alt="Abemaciclib intermediate product detail showing CAS, purity, and storage conditions"]

Frequently Asked Questions

[MAGE: CTA | Download brochure or contact | alt="Haohong Pharmaceutical company profile download button"]

Conclusion

For pharmaceutical companies developing targeted cancer therapies, the choice of intermediate supplier directly affects API quality, cost, and regulatory timelines. Haohong (Qihe) Pharmaceutical Technology Co., Ltd. delivers high-purity, GMP-ready intermediates for Apalutamide, Alectinib, Abemaciclib, and many other advanced oncology projects. With ISO 9001:2015 certification, a 30-engineer R&D team, 1,000-ton annual capacity, and proven export experience to major markets, Haohong offers a reliable partner for both custom synthesis and bulk supply. Contact the team to discuss your specific intermediate requirements.